One of the main tasks in the fight against cancer is the early diagnosis of a tumor. Even better – to predict the occurrence of the disease in advance. Microchips based on synthetic antigens can help this.
08.07.2009Increasingly faced with the problem of the expiration of patent exclusivity for their original medicines, representatives of Big Pharma are increasingly inclined to a hybrid brand-generic model.
06.07.2009There is no need to build illusions that the pharmaceutical market will be opened to domestic drugs just like that, where competition is very strong. The organization of any pharmaceutical production in the country receives tremendous opposition from all sides, which probably have their own interests in ensuring that the market situation does not change.
24.06.2009Academician Anatoly Miroshnikov: "Russia, apparently, needs a big trouble to understand how important it is to have its own pharmaceutical industry with a full cycle of creating at least vital drugs."
22.06.2009He was the youngest professor at Moscow State University, winner of the Lenin Komsomol Prize and winner of the USSR State Prize. He now lives in Boston. Anatoly Klesov has passed the classic path of an innovator, about which a lot of textbooks are written. And now he is a shareholder of an enterprise that uses his developments in the field of composite materials and vice president of a biotech company developing anti-cancer drugs.
15.06.2009The problem is that even large pharmaceutical companies practically do not deal with antibiotics, more precisely, cheap antibiotics that are used to treat social diseases. In Russia, they are not engaged in any antibiotics and do not plan to.
03.06.2009Domestic pharmaceutical manufacturers do not have any incentives for research activities: loans and debt instruments are expensive, venture financing is poorly developed, there are no preferences for domestic producers in public procurement.
29.05.2009According to the General director of Biocad, D.Morozov, the development of the domestic pharmaceutical industry is hindered by the "stagnant" mentality of scientists and the vulnerability of domestic companies to Western pharmaceutical giants that have occupied the Russian market.
12.05.2009In the field of biosensors, the Laboratory of Electrochemical Methods of Moscow State University occupies a leading position at the world level. These devices are significantly superior in their capabilities to foreign analogues, and they can be used almost everywhere: from medicine to industrial ecology. But cheap, simple and selective analyses that can be carried out using biosensors are still underestimated in Russia.
15.04.2009The Russian biotechnological innovation company "Eurogen" sells its technologies and products all over the world. Lukyanov is convinced that his company, armed with modern devices, would have a real chance to make a revolution in biomedicine and take a leading position in the development of new approaches to the treatment of oncological and autoimmune diseases. He knows other companies that could "jerk" if not for financial constraints.
13.04.2009The analysis was carried out only in those areas of life sciences, the results of which have a pronounced applied value: bioinformatic, biocatalytic, biosynthetic and biosensory technologies, biomedical and veterinary technologies for life support and protection of humans and animals, genomic and postgenomic technologies for the creation of medicines, cellular technologies, bioengineering technologies, technologies for the creation of biocompatible materials.
09.04.2009In order for Russians to be able to buy domestic generic drugs in pharmacies that are not inferior to imported analogues, the Russian pharmaceutical industry needs modern equipment and qualified personnel. If you translate this phrase into the language of economics, then by and large, nothing but huge investments are needed for domestic pharma. Moreover, money will have to be invested not only directly in the pharmaceutical industry, but also in science and education.
02.04.2009The crisis gives a few Russian developers of innovative pharmaceuticals a chance to attract the attention of Big Pharma and expand their market share.
27.03.2009On the basis of peptides, scientists create neuroprotective drugs that successfully combat the most severe disorders of the nervous system – neurasthenia, stroke, leading to the death of brain neurons and, as a consequence, paralysis and paresis.
23.03.2009Advanced domestic pharmaceutical manufacturers, having invested considerable sums in R& D and in the modernization of production, began to produce analogues of imported drugs, but local pharmaceutical manufacturers cannot "break through" with their products into public procurement.
17.03.2009One of the foundations of the "knowledge economy", based not on production, but on the sale of know-how, is the rapid turnover of knowledge. However, it is not clear how quickly knowledge is ready to "turn around". We will consider this question on a concrete example of the introduction of one of the achievements of fundamental science into life.
13.03.2009RUSNANO presented the statistics of the examination of applications received by the corporation for 2008. At the initial stage of evaluation, 125 investment projects were accepted for consideration, 40 of them successfully passed the examination and 50 were rejected. The most applications were submitted in the field of materials science – 44, physics – 26 in second place, biology and medicine – 22 projects closed the top three.
19.02.2009The creation of innovative medicines was discussed at the meeting of the Presidium of the Russian Academy of Sciences.
12.02.2009The Association of Russian Pharmaceutical Manufacturers (ARFP) believes that it is strategically important to support full-cycle enterprises producing active substances and take the necessary measures to restore lost production facilities.
12.02.2009Biotechnologies and medicine are recognized as priority areas of investment due to the need to solve the most pressing problems facing British society - the problems of population aging and energy. In addition, the achievements of the country's scientists in these areas are recognized as the most significant and promising, and their stimulation will allow British science to maintain and strengthen world leadership.
06.02.2009
You can write to the editor at:
vm@vechnayamolodost.ruThe editors of Eternal Youth are preparing a useful and interesting mailing list. You can get it if you leave your mail.